Key facts
- It has raised $250K; the latest was Later Stage VC in Mar 2026.
- Notable investors include Robin Hood Ventures, Mountain State Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Innervate Radiopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Innervate Radiopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Innervate Radiopharmaceuticals
Developer of positron emission tomography (PET) imaging and therapeutic radiopharmaceuticals intended to improve image resolution. The company offers an imaging biomarker that has significant advantages over single photon emission computed tomography (SPECT), the current standard of care for biomarker imaging in neuroblastoma patients, enabling the healthcare industry to improve reliability and accuracy in the detection of disease, in turn, leading to important improvements in patient management and outcomes for patients with neuroblastoma and potentially other diseases.
- Sector
- Healthcare
- HQ
- Englewood, NJ, United States
- Founded
- 2019
- Website
- innervaterp.com/
- Ownership
- Privately Held (backing)
Innervate Radiopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Innervate Radiopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Innervate Radiopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.